fluorescent ligands
11 September 2025
Sigma receptor 1 in CNS disorders and drug discovery. Discover how targeted assays and fluorescent ligands enhance selectivity and therapeutic potential.
30 June 2025
GPCR and drug discovery: how fluorescent ligands streamline target identification for faster, more accurate screening.
21 February 2025
Studying receptor-ligand interaction is a crucial approach in drug discovery and biomedical research. Radioligands have been the gold standard for binding assays since their first use […]
16 January 2024
We are very proud to present our last paper in collaboration with the Institute of Neuroscience of the Universitat de Barcelona, the CiQUS – Center for Research in […]
18 October 2023
Sigma (σ) receptor subtypes, σ1 and σ2, are targets of wide pharmaceutical interest. σ1 receptor ligands are under evaluation in clinical trials for the treatment of diseases such as […]
19 July 2023
Traditional pharmacological mechanisms leave a significant part of the genome ‘undruggable’, due to the inability to induce or block their activity using agonists and antagonists. Thanks […]
13 July 2023
Celtarys expands its presence in the GPCR field, developing new applications in collaboration agreement with Nanotemper, a company devoted to the development of innovative instruments for […]
27 January 2023
WHY IS IMPORTANT TO CONSIDER MULTIPLE ASSAY TYPES FOR TARGETS CHARACTERIZATION? Usually, in the identification of new drug-like molecules for a target of interest it is […]
26 January 2023
Custom synthesis service for fluorescent ligands Celtarys provides custom chemical development services, specifically for the identification of a broad range of robust and complex fluorescent ligands […]